18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
Recruitment status was Recruiting
Positron emission tomography (PET) is a nuclear medicine procedure based on the measurement of positron emission from radiolabelled tracer molecules. These radiotracers allow biologic processes to be measured and whole body images to be obtained which demonstrates sites of radiotracer accumulation. The most common radiotracer in use today is 18F-fluorodeoxyglucose (18F-FDG) which is a radiolabelled sugar (glucose) molecule. Imaging with 18F-FDG PET is used to determine sites of abnormal glucose metabolism and can be used to characterize and localize many types of tumours.
Cancer treatment and outcome depend largely on the accurate diagnosis and staging of disease. There is extensive data in the literature indicating the importance of FDG-PET imaging in accurately characterizing disease, as well as determining stage and sites of recurrent disease in many cancer types. For these indications, functional imaging with PET provides unique information which is not available from standard medical imaging modalities such as ultrasound, X-ray, computerized tomography (CT) or magnetic resonance imaging (MRI).
The objectives of this study are to document the safety and efficacy of 18F-FDG produced by the British Columbia Cancer Agency (BCCA) at its Tri-University Meson Facility (TRIUMF) production facility and to evaluate FDG-PET as a diagnostic and decision making tool in the management of oncology patients in British Columbia. With a population base of over 4 million people, standardized cancer treatment protocols, and evidence based guidelines for FDG-PET imaging, the BCCA is positioned to make an important contribution to defining the role of PET in the Canadian health care system.
Procedure: Positron Emission Tomography
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Phase III Open Label Trial for Use of [18F]-Fluoro-Deoxy-Glucose (18F-FDG) in Positron Emission Tomography Imaging in Oncology|
- Change in management based on PET procedure
- Sensitivity of PET
|Study Start Date:||June 2005|
|Estimated Study Completion Date:||November 2008|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00207298
|Contact: Don C Wilson, MDfirstname.lastname@example.org|
|Canada, British Columbia|
|BCCA, Vancouver Centre||Recruiting|
|Vancouver, British Columbia, Canada, V5Z 4E6|
|Contact: Don C Wilson, MD 604-707-5979 email@example.com|
|Principal Investigator:||Don C Wilson, MD||British Columbia Cancer Agency|